# WIA-MED-011: Smart Pill Standard v1.0

## Metadata

- **Standard ID**: WIA-MED-011
- **Title**: Smart Pill - Ingestible Sensor Standard
- **Emoji**: 💊
- **Version**: 1.0.0
- **Status**: Active
- **Date**: 2025-01-15
- **Category**: Medical Devices
- **Folder**: smart-pill

## Abstract

This standard defines requirements, protocols, and best practices for smart pill (ingestible sensor) technology including sensors, wireless communication, drug delivery, biocompatible materials, and regulatory compliance.

## 1. Scope

This standard applies to:
- Ingestible electronic devices for health monitoring
- Medication adherence tracking systems
- Controlled drug delivery capsules
- GI tract diagnostic devices
- Wireless data transmission from inside the body

## 2. Normative References

- ISO 10993: Biological evaluation of medical devices
- ISO 13485: Medical devices quality management systems
- ISO 14155: Clinical investigation of medical devices
- 21 CFR Part 11: Electronic records and signatures
- 21 CFR Part 820: Quality System Regulation (QSR)
- IEC 60601-1: Medical electrical equipment safety
- IEEE 802.15.6: Wireless body area networks

## 3. Terms and Definitions

### 3.1 Smart Pill
Ingestible electronic capsule containing sensors, microprocessor, wireless transmitter, and power source for health monitoring and/or drug delivery.

### 3.2 Biocompatibility
Ability of materials to perform with appropriate host response in specific application (ISO 10993).

### 3.3 GI Transit Time
Duration for capsule passage through gastrointestinal tract from ingestion to excretion.

### 3.4 MICS (Medical Implant Communication Service)
Radio spectrum (402-405 MHz) designated for medical implant devices.

## 4. System Architecture

### 4.1 Core Components

```
SmartPill {
  Sensing Layer:
    - pH sensors (ISFET, range 1.0-9.0, ±0.1 pH)
    - Temperature sensors (NTC, 30-45°C, ±0.05°C)
    - Pressure sensors (MEMS, 0-400 mmHg, ±1 mmHg)
    - Biochemical sensors (glucose, lactate, O₂)
    - Imaging sensors (CMOS, up to 1280x1024)

  Processing Layer:
    - Microcontroller (ARM Cortex ultra-low-power)
    - ADC (12-16 bit, 10 Hz - 10 kHz)
    - Data compression (lossless/lossy)
    - Encryption (AES-256)

  Communication Layer:
    - RF transmitter (MICS 402-405 MHz or ISM 2.4 GHz)
    - Antenna (biocompatible, integrated)
    - Power: < 1-10 mW
    - Range: 1-3 meters

  Power Layer:
    - Battery (Ag₂O, Li, Zn-Air, 10-100 mAh)
    - Energy harvesting (gastric acid, thermoelectric)
    - Power management IC

  Encapsulation Layer:
    - Capsule (gelatin, HPMC, enteric polymers)
    - Sealing (medical epoxy/silicone)
    - Drug reservoir (optional, controlled release)
}
```

### 4.2 Size Requirements

- Maximum diameter: 15 mm (ileocecal valve constraint)
- Typical range: 8-12 mm
- Minimum size (pediatric): 6-8 mm

## 5. Technical Specifications

### 5.1 Sensor Performance

| Parameter | Range | Accuracy | Resolution | Response |
|-----------|-------|----------|------------|----------|
| pH | 1.0 - 9.0 | ±0.1 | 0.01 | <30s |
| Temperature | 30-45°C | ±0.05°C | 0.01°C | <10s |
| Pressure | 0-400 mmHg | ±1 mmHg | 0.1 mmHg | Real-time |
| Glucose | 0-500 mg/dL | ±10 mg/dL | 1 mg/dL | <60s |

### 5.2 Wireless Communication

- **MICS Band**: 402-405 MHz, 300 kHz bandwidth, EIRP ≤ 25 μW
- **ISM Band**: 2.4 GHz, data rate 250 kbps - 2 Mbps
- **Protocols**: BLE 4.0+, Zigbee, proprietary
- **Security**: AES-256 encryption, HMAC-SHA256 authentication
- **Link budget**: Minimum 20 dB margin for reliable transmission

### 5.3 Power Specifications

- **Operating voltage**: 1.5-3.0 V
- **Average power consumption**: < 5 mW
- **Battery life**: 8-72 hours (application dependent)
- **Energy harvesting**: 10-100 μW (gastric acid galvanic cell)

## 6. Drug Delivery Requirements

### 6.1 Release Mechanisms

- **Time-controlled**: Zero-order or first-order kinetics
- **pH-triggered**: Enteric coatings (Eudragit L100, S100, HPMCP)
- **Enzyme-triggered**: Bacterial azoreductase, glycosidases
- **Electronic**: Electroporation, iontophoresis, MEMS valves

### 6.2 Dosage Accuracy

- **Content uniformity**: 85-115% of label claim (USP <905>)
- **Release profile**: ±15% from specification
- **Targeting accuracy**: ±20 cm for regional delivery

## 7. Material Requirements

### 7.1 Biocompatibility

All materials SHALL comply with:
- ISO 10993-1: Risk management
- ISO 10993-5: Cytotoxicity (cell viability > 70%)
- ISO 10993-10: Irritation and sensitization
- ISO 10993-11: Systemic toxicity
- USP Class VI (for high-risk contact)

### 7.2 Approved Materials

**Capsules**:
- Gelatin (USP/Ph.Eur grade)
- HPMC (vegetarian alternative)
- Enteric polymers (Eudragit, HPMCP, shellac)
- Biodegradable (PLGA, PLA, PCL)

**Coatings**:
- Nafion (sensor selectivity)
- Polyurethane (protection)
- Cellulose acetate (MW cutoff)
- PEG/zwitterionic (anti-fouling)

### 7.3 Degradation

- **Non-degradable**: Safe excretion < 72 hours
- **Biodegradable**: Complete absorption or excretion within specified timeline
- **Products**: Non-toxic metabolites only

## 8. Safety Requirements

### 8.1 Design Safety

- **Size**: < 15 mm maximum (obstruction prevention)
- **Shape**: Rounded edges, smooth surface
- **Battery**: Double-sealed, non-reactive encapsulation
- **MRI**: Clearly labeled (unsafe/conditional/safe)

### 8.2 Contraindications

- Known GI obstruction or strictures
- Recent GI surgery (< 6 months)
- Severe dysphagia
- Pregnancy (some procedures)
- Scheduled MRI before excretion

### 8.3 Risk Mitigation

- **Obstruction**: < 0.01% incidence, patency capsule screening
- **Perforation**: < 0.001% incidence, design optimization
- **Aspiration**: Conscious swallowing, upright position
- **Battery leakage**: Rigorous seal testing, biocompatible materials

## 9. Data Management

### 9.1 Data Collection

- **Sampling rate**: Configurable (1 Hz - 100 Hz)
- **Storage**: Local buffering (1-10 KB)
- **Compression**: 2:1 to 10:1 ratio
- **Transmission**: Real-time or batch upload

### 9.2 Data Security

- **Encryption**: AES-256 (data at rest and in transit)
- **Authentication**: HMAC-SHA256, mutual authentication
- **Integrity**: Checksums, sequence numbers
- **Privacy**: HIPAA, GDPR compliance

### 9.3 Data Quality

- **Validation**: Automated range checking, artifact rejection
- **Calibration**: Factory calibration with NIST-traceable standards
- **Accuracy**: Meet or exceed sensor specifications (Section 5.1)

## 10. Regulatory Compliance

### 10.1 United States (FDA)

- **Class II**: 510(k) premarket notification (most sensors)
- **Class III**: PMA premarket approval (imaging, novel therapeutics)
- **Clinical trials**: IDE (SR or NSR), GCP compliance
- **Post-market**: MDR reporting, QSR (21 CFR 820)

### 10.2 European Union (MDR 2017/745)

- **Classification**: Class IIa or IIb (Annex VIII)
- **CE marking**: Notified Body assessment
- **Clinical evaluation**: MEDDEV 2.7/1 guidelines
- **Post-market**: PMCF, vigilance reporting, EUDAMED

### 10.3 International

- **Japan (PMDA)**: Class II-III, Japanese clinical data
- **China (NMPA)**: Class III, Chinese clinical trials
- **ISO 13485**: QMS certification (global)

## 11. Testing Requirements

### 11.1 Benchtop Testing

- Sensor accuracy and linearity
- Battery life and power consumption
- Wireless range and link budget
- Mechanical strength (compression, drop)
- Environmental (temperature, humidity, vibration)

### 11.2 Biocompatibility Testing

- Cytotoxicity (ISO 10993-5)
- Sensitization (ISO 10993-10)
- Systemic toxicity (ISO 10993-11)
- Hemolysis (ISO 10993-4)
- GI-specific (mucosal irritation, enzyme stability)

### 11.3 Clinical Testing

- Phase I: Safety/feasibility (10-30 subjects)
- Phase II: Pilot efficacy (50-100 subjects)
- Phase III: Pivotal efficacy (100-500+ subjects)
- Post-market: Real-world performance (hundreds-thousands)

## 12. Quality Management

### 12.1 Design Controls

- Design and development planning
- Design inputs (user needs, specifications)
- Design outputs (drawings, code, test procedures)
- Design verification (meets outputs)
- Design validation (meets user needs)
- Design transfer (production)
- Design changes (controlled)

### 12.2 Manufacturing

- Process validation (IQ, OQ, PQ)
- Statistical process control
- In-process testing
- Final inspection and testing
- Sterilization (if applicable, validated)

### 12.3 Traceability

- Device History Record (DHR)
- Unique Device Identifier (UDI)
- Lot/serial number tracking
- Component traceability

## 13. Clinical Integration

### 13.1 Indications for Use

- GI motility assessment (gastroparesis, constipation)
- pH monitoring (GERD, Barrett's esophagus)
- Small bowel imaging (bleeding, tumors, Crohn's)
- Medication adherence monitoring
- Targeted drug delivery (IBD, infections, cancer)

### 13.2 Workflow

1. Patient screening (indications, contraindications)
2. Informed consent (risks, benefits, alternatives)
3. Patient preparation (dietary, medications, education)
4. Capsule ingestion (clinical or home setting)
5. Monitoring period (8-72 hours, normal activities)
6. Data analysis (automated + physician review)
7. Results communication and treatment planning

### 13.3 Patient Support

- Multilingual education materials
- 24/7 hotline (for concerns)
- Diary tools (app or paper)
- Excretion confirmation process

## 14. Future Considerations

### 14.1 Emerging Technologies

- Molecular sensors (proteomics, metabolomics, genomics)
- Advanced imaging (OCT, multispectral)
- AI edge processing (TinyML, CNN)
- Controlled navigation (magnetic, active locomotion)
- Interventional (biopsy, hemostasis, ablation)

### 14.2 Roadmap

- **Near-term (1-3 yr)**: Miniaturization, improved battery, additional sensors
- **Mid-term (3-7 yr)**: Theranostics (closed-loop), autonomous navigation
- **Long-term (7-15 yr)**: Nanorobots, predictive medicine, symbiotic devices

## 15. Conformance

Devices claiming conformance to WIA-MED-011 SHALL:
1. Meet all requirements in Sections 4-8 (SHALL statements)
2. Comply with applicable regulatory requirements (Section 10)
3. Complete testing per Section 11
4. Implement quality management per Section 12
5. Provide technical documentation demonstrating compliance

---

## Appendix A: Example Implementation

See `/home/user/wia-standards/smart-pill/ebook/` for comprehensive ebooks
covering all aspects of smart pill technology implementation.

## Appendix B: Code Examples

(To be developed: TypeScript SDK, API definitions)

## Appendix C: Test Protocols

(To be developed: Detailed test procedures)

---

**License**: MIT License
**Philosophy**: 弘益人間 (Benefit All Humanity)

© 2025 WIA - World Certification Industry Association
